
|Videos|December 13, 2021
Dr. Morris on Lutetium 177 PSMA: “We have a lot of work to do”
Author(s)Urology Times staff
We have a lot of work to do to define how to optimize the integration of this therapy into what we call ‘advanced prostate cancer’,” says Michael J. Morris, MD.
Advertisement
In this video, Michael J. Morris, MD, discusses what the impact of the VISION trial will be on clinical practices, which are ideas that were focused on at the 2021 Society of Urologic Oncology Annual Meeting. Morris is the section head of prostate cancer in the GU oncology service at the Memorial Sloan Kettering Cancer Center in New York, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












